NCT04038619 2026-03-18
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
49 trialsNCT06801067 2025-12-02
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03767257 2025-10-21
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT06892093 2025-09-08
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Recruiting
NCT06576986 2024-08-29
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
Federal University of Minas Gerais
Phase NA Recruiting
NCT04926545 2024-07-30
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Guangzhou University of Traditional Chinese Medicine
Phase NA Completed
NCT02944617 2024-02-23
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
City of Hope Medical Center
Phase NA Completed
NCT06152471 2023-11-30
ASF-BC
Uppsala University Hospital
Phase 3 Unknown
NCT06019312 2023-08-31
L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer Patients
Medical University of Gdansk
Phase NA Unknown
NCT00003057 2023-06-18
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00444093 2023-05-11
Loop
Philipps University Marburg
Phase 3 Terminated
NCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT02819960 2022-12-14
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o.
Phase 3 Completed
NCT03722511 2022-11-03
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
University of Kentucky
Phase 2 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00197873 2021-11-24
Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea
University of Helsinki
Phase NA Completed
NCT05091775 2021-10-25
The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure
Shiraz University of Medical Sciences
Phase 1/2 Completed
NCT04003181 2021-09-08
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
University of Aarhus
Phase NA Completed
NCT02814864 2021-08-03
PRISME
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT04874883 2021-05-06
Effect of the Use of Symbiotics in Patients With Colon Cancer
Federal University of Minas Gerais
Phase 4 Unknown
NCT04736186 2021-02-03
Prevention and Treatment of Pyrrolitinib-associated Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT01371656 2020-12-07
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group
Phase 3 Completed
NCT00748215 2020-12-02
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00258401 2020-07-27
Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.
Case Comprehensive Cancer Center
Phase NA Completed
NCT01198145 2020-05-12
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04040712 2020-03-17
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Catholic University of the Sacred Heart
Phase NA Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT02080078 2019-05-03
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
AHS Cancer Control Alberta
Phase 1 Terminated
NCT02018653 2018-07-26
CASAD for Severe Diarrhea in the Emergency Department
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00143533 2017-04-26
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01523431 2017-03-30
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2/3 Completed
NCT00040391 2016-12-01
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Celgene Corporation
Phase 2 Terminated
NCT00033605 2016-07-13
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01473290 2016-07-06
Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT01164215 2015-10-09
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00582426 2015-05-04
LARCID
Novartis
Phase 3 Completed
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated
NCT01543451 2014-03-26
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
Helsinn Healthcare SA
Phase 2 Completed
NCT01644097 2014-02-14
Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy
Stanford University
Phase 2 Withdrawn
NCT01410955 2014-01-23
Prevention of Irinotecan Induced Diarrhea by Probiotics
Monsea Ltd.
Phase 3 Completed
NCT00084721 2013-01-31
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT01438645 2013-01-17
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
University of Alberta
Phase NA Completed
NCT01739634 2012-12-03
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Salient Pharmaceuticals Incorporated
Phase 1/2 Unknown
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00093353 2010-10-15
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Children's Hospital Los Angeles
Phase 1 Completed
NCT00050635 2009-11-19
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Novartis
Phase 4 Completed
NCT00036517 2005-06-24
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
PhytoCeutica
Phase 1/2 Terminated